KMT2D deficiency potentiates antitumor immunity and sensitizes immune checkpoint blockade in urologic cancers
The Journal of Pathology · 2025
DOI: 10.1002/path.6481 ↗At a glance
Journal article in The Journal of Pathology, 2025. Written by Yuedian Ye and 13 co-authors. Institution: Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, PR China. Major MEDLINE topics: Immune Checkpoint Inhibitors, DNA-Binding Proteins, Urologic Neoplasms, Neoplasm Proteins. 39 references. Funded by: Natural Science Foundation of Jiangxi Province, Science and Technology Program of Ganzhou City, Ganpo Talent Support Program - Major Discipline Academic and Technological Leader Training Project.
Abstract (original language)
Immune checkpoint blockade (ICB) therapy has made remarkable advances in cancer treatment. However, the overall response rate remains limited. Here, we aim to explore the role of histone 3 lysine 4 mono‐methyltransferase KMT2D in tumor immune response and improve the efficacy of ICB. We developed a patient‐derived urologic tumor fragment (PDUTF) platform comprising 56 tumors and constructed three major urological tumor tissue microarrays from 356 patients. Analyzed using the PDUTF platform and tissue microarrays (TMAs), we found that tumors with KMT2D deficiency were associated with enhanced T‐cell activation in response to anti‐PD‐1 therapy and exhibited increased T‐cell infiltration. Subsequently, T‐cell migration and T‐cell‐mediated tumor cell killing assays revealed that the deletion of KMT2D in cancer cells promoted CD8 + T‐cell migration and cytotoxicity against tumor cells. Mechanistically, the loss of KMT2D enhanced antitumor immunity by promoting chemokine‐mediated recruitment of T cells both in vitro and in vivo . Finally, the small‐molecule inhibitor MI‐503 combined with anti‐PD‐1 therapy suppressed tumor growth on the PDUTF platform. Collectively, KMT2D deficiency sensitizes tumor cells to ICB, and inhibiting KMT2D may represent a promising approach in combination with ICB to improve patient prognosis. © 2025 The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.
- Department of Urology, The First People's Hospital of Nanning, Nanning, PR China.
- Department of Urology, The Ninth People's Hospital of Nanning, Nanning, PR China.
- Department of Urology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, PR China.
ORCID profiles: Qiang Wei
Funding
- Natural Science Foundation of Jiangxi Province
- Science and Technology Program of Ganzhou City
- Ganpo Talent Support Program - Major Discipline Academic and Technological Leader Training Project
- Bethune Oncology Basic Research Program
- Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
Cite
APA
Ye, Y., Liao, Y., Zhang, Y., Zhang, J., Luo, M., Yang, Q., Zhai, Q., Xu, Z., Wang, Y., Wen, H., Wu, C., Qiu, Y., Lv, S., & Wei, Q. (2025). KMT2D deficiency potentiates antitumor immunity and sensitizes immune checkpoint blockade in urologic cancers. The Journal of Pathology. https://doi.org/10.1002/path.6481
Vancouver
Ye Y, Liao Y, Zhang Y, Zhang J, Luo M, Yang Q, et al. KMT2D deficiency potentiates antitumor immunity and sensitizes immune checkpoint blockade in urologic cancers. The Journal of Pathology. 2025. doi:10.1002/path.6481
BibTeX
@article{Ye2025,
author = {Ye, Yuedian and Liao, Yuanpeng and Zhang, Yifan and Zhang, Jianqiang and Luo, Mayao and Yang, Qiao and Zhai, Qiliang and Xu, Zhuofan and Wang, Yutong and Wen, Haoran and Wu, Chenwei and Qiu, Yang and Lv, Shidong and Wei, Qiang},
title = {KMT2D deficiency potentiates antitumor immunity and sensitizes immune checkpoint blockade in urologic cancers},
journal = {The Journal of Pathology},
year = {2025},
doi = {10.1002/path.6481}
}
EUVIMED